Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function
Objective: Serum cystatin C (CysC) is a sensitive marker of renal function to predict cardiovascular diseases. We aimed to investigate the predictive value of CysC for clinical outcomes independent of renal function in patients with acute ischemic stroke (AIS).Methods: We measured serum CysC levels...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.676872/full |
id |
doaj-4f298b8a59194d96a3058a3aec7b9f24 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yarong Ding Yarong Ding Yarong Ding Yarong Ding Liping Liu Liping Liu Liping Liu Liping Liu Zimo Chen Zimo Chen Zimo Chen Zimo Chen Hao Li Hao Li Hao Li Hao Li Yuesong Pan Yuesong Pan Yuesong Pan Yuesong Pan Junfeng Wang Xia Meng Xia Meng Xia Meng Xia Meng Jinxi Lin Jinxi Lin Jinxi Lin Jinxi Lin Jing Jing Jing Jing Jing Jing Jing Jing Xuewei Xie Xuewei Xie Xuewei Xie Xuewei Xie Xianglong Xiang Xianglong Xiang Xianglong Xiang Xianglong Xiang Yongjun Wang Yongjun Wang Yongjun Wang Yongjun Wang |
spellingShingle |
Yarong Ding Yarong Ding Yarong Ding Yarong Ding Liping Liu Liping Liu Liping Liu Liping Liu Zimo Chen Zimo Chen Zimo Chen Zimo Chen Hao Li Hao Li Hao Li Hao Li Yuesong Pan Yuesong Pan Yuesong Pan Yuesong Pan Junfeng Wang Xia Meng Xia Meng Xia Meng Xia Meng Jinxi Lin Jinxi Lin Jinxi Lin Jinxi Lin Jing Jing Jing Jing Jing Jing Jing Jing Xuewei Xie Xuewei Xie Xuewei Xie Xuewei Xie Xianglong Xiang Xianglong Xiang Xianglong Xiang Xianglong Xiang Yongjun Wang Yongjun Wang Yongjun Wang Yongjun Wang Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function Frontiers in Neurology cystatin C renal function biomarker ischemic stroke clinical outcomes |
author_facet |
Yarong Ding Yarong Ding Yarong Ding Yarong Ding Liping Liu Liping Liu Liping Liu Liping Liu Zimo Chen Zimo Chen Zimo Chen Zimo Chen Hao Li Hao Li Hao Li Hao Li Yuesong Pan Yuesong Pan Yuesong Pan Yuesong Pan Junfeng Wang Xia Meng Xia Meng Xia Meng Xia Meng Jinxi Lin Jinxi Lin Jinxi Lin Jinxi Lin Jing Jing Jing Jing Jing Jing Jing Jing Xuewei Xie Xuewei Xie Xuewei Xie Xuewei Xie Xianglong Xiang Xianglong Xiang Xianglong Xiang Xianglong Xiang Yongjun Wang Yongjun Wang Yongjun Wang Yongjun Wang |
author_sort |
Yarong Ding |
title |
Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function |
title_short |
Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function |
title_full |
Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function |
title_fullStr |
Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function |
title_full_unstemmed |
Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal Function |
title_sort |
serum cystatin c predicts stroke clinical outcomes at 1 year independent of renal function |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2021-08-01 |
description |
Objective: Serum cystatin C (CysC) is a sensitive marker of renal function to predict cardiovascular diseases. We aimed to investigate the predictive value of CysC for clinical outcomes independent of renal function in patients with acute ischemic stroke (AIS).Methods: We measured serum CysC levels in 10,256 AIS patients from Third China National Stroke Registry (CNSR-III). The primary outcome was a combination of all-cause mortality and major disability (modified Rankin scale score, 3–6). Secondary outcomes included stroke recurrence and combined vascular events at 1 year. Outcomes were analyzed using logistic regression and Cox proportional hazards models, respectively.Results: The median CysC of included patients was 0.95 mg/l (interquartile range, 0.83–1.10 mg/l). A U-shaped association was observed between CysC and primary outcome (all-cause mortality or major disability) [quartile (Q)1 vs. Q2: adjusted odds ratio (aOR) 1.29, 95% CI 1.06–1.58, p = 0.012; Q3 vs. Q2: aOR 1.12, 95% CI 0.93–1.35, p = 0.242; Q4 vs. Q2: aOR 1.35, 95% CI 1.10–1.65, p = 0.004]. A similar trend also existed in “preserved renal function” patients. Adding CysC to a model containing conventional risk factors improved the model performance with integrated discrimination improvement (IDI) of 0.13% (p = 0.016) and net reclassification index (NRI) of 13.10% (p <0.001) for primary outcome. No significant association was observed for stroke recurrence or combined vascular event rate in different CysC quartiles.Conclusions: CysC showed a U-shaped correlation with 1-year stroke clinical outcome, suggesting that serum CysC may not only be a simple candidate marker of renal function. |
topic |
cystatin C renal function biomarker ischemic stroke clinical outcomes |
url |
https://www.frontiersin.org/articles/10.3389/fneur.2021.676872/full |
work_keys_str_mv |
AT yarongding serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yarongding serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yarongding serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yarongding serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT lipingliu serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT lipingliu serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT lipingliu serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT lipingliu serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT zimochen serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT zimochen serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT zimochen serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT zimochen serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT haoli serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT haoli serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT haoli serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT haoli serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yuesongpan serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yuesongpan serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yuesongpan serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yuesongpan serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT junfengwang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xiameng serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xiameng serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xiameng serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xiameng serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jinxilin serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jinxilin serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jinxilin serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jinxilin serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jingjing serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jingjing serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jingjing serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT jingjing serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xueweixie serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xueweixie serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xueweixie serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xueweixie serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xianglongxiang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xianglongxiang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xianglongxiang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT xianglongxiang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yongjunwang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yongjunwang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yongjunwang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction AT yongjunwang serumcystatincpredictsstrokeclinicaloutcomesat1yearindependentofrenalfunction |
_version_ |
1721211613196845056 |
spelling |
doaj-4f298b8a59194d96a3058a3aec7b9f242021-08-11T05:02:52ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-08-011210.3389/fneur.2021.676872676872Serum Cystatin C Predicts Stroke Clinical Outcomes at 1 Year Independent of Renal FunctionYarong Ding0Yarong Ding1Yarong Ding2Yarong Ding3Liping Liu4Liping Liu5Liping Liu6Liping Liu7Zimo Chen8Zimo Chen9Zimo Chen10Zimo Chen11Hao Li12Hao Li13Hao Li14Hao Li15Yuesong Pan16Yuesong Pan17Yuesong Pan18Yuesong Pan19Junfeng Wang20Xia Meng21Xia Meng22Xia Meng23Xia Meng24Jinxi Lin25Jinxi Lin26Jinxi Lin27Jinxi Lin28Jing Jing29Jing Jing30Jing Jing31Jing Jing32Xuewei Xie33Xuewei Xie34Xuewei Xie35Xuewei Xie36Xianglong Xiang37Xianglong Xiang38Xianglong Xiang39Xianglong Xiang40Yongjun Wang41Yongjun Wang42Yongjun Wang43Yongjun Wang44Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, NetherlandsDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCenter of Stroke, Beijing Institute for Brain Disorders, Beijing, ChinaBeijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, ChinaObjective: Serum cystatin C (CysC) is a sensitive marker of renal function to predict cardiovascular diseases. We aimed to investigate the predictive value of CysC for clinical outcomes independent of renal function in patients with acute ischemic stroke (AIS).Methods: We measured serum CysC levels in 10,256 AIS patients from Third China National Stroke Registry (CNSR-III). The primary outcome was a combination of all-cause mortality and major disability (modified Rankin scale score, 3–6). Secondary outcomes included stroke recurrence and combined vascular events at 1 year. Outcomes were analyzed using logistic regression and Cox proportional hazards models, respectively.Results: The median CysC of included patients was 0.95 mg/l (interquartile range, 0.83–1.10 mg/l). A U-shaped association was observed between CysC and primary outcome (all-cause mortality or major disability) [quartile (Q)1 vs. Q2: adjusted odds ratio (aOR) 1.29, 95% CI 1.06–1.58, p = 0.012; Q3 vs. Q2: aOR 1.12, 95% CI 0.93–1.35, p = 0.242; Q4 vs. Q2: aOR 1.35, 95% CI 1.10–1.65, p = 0.004]. A similar trend also existed in “preserved renal function” patients. Adding CysC to a model containing conventional risk factors improved the model performance with integrated discrimination improvement (IDI) of 0.13% (p = 0.016) and net reclassification index (NRI) of 13.10% (p <0.001) for primary outcome. No significant association was observed for stroke recurrence or combined vascular event rate in different CysC quartiles.Conclusions: CysC showed a U-shaped correlation with 1-year stroke clinical outcome, suggesting that serum CysC may not only be a simple candidate marker of renal function.https://www.frontiersin.org/articles/10.3389/fneur.2021.676872/fullcystatin Crenal functionbiomarkerischemic strokeclinical outcomes |